U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Nurse Assist, Inc - 524298 - 04/01/2020
  1. Warning Letters

CLOSEOUT LETTER

Nurse Assist, Inc MARCS-CMS 524298 —

Delivery Method:
UPS Overnight
Product:
Medical Devices
Recipient:
Recipient Name
Kevin J. Seifert
Recipient Title
President and Chief Executive Officer
Nurse Assist, Inc

4409 Haltom Road
Haltom City, TX 76117
United States

Issuing Office:
Office of Medical Devices and Radiological Health Division III

United States

Dear Mr. Seifert:

The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter dated May 8, 2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Jessica Mu,
Director, Compliance Branch
Office of Medical Devices and
Radiological Health, Division III

Back to Top